Novo Nordisk wins Dutch injunction in semaglutide patent case

• The injunction targets Ceban Ziekenhuisfarmacie B.V., a Netherlands-based entity producing a compounded semaglutide nasal spray
• Semaglutide is the key ingredient in Novo Nordisk's highly profitable medications, making patent protection commercially critical
• The preliminary injunction represents an early legal victory for Novo Nordisk in defending its semaglutide patents against unauthorized competitors

Summary

Key Development:

Novo Nordisk has secured a preliminary injunction from a Dutch district court against Ceban Ziekenhuisfarmacie B.V. in a patent infringement case involving a compounded semaglutide nasal spray. The announcement was made on August 5.

Companies Involved:

• Novo Nordisk (plaintiff): Danish pharmaceutical manufacturer
• Ceban Ziekenhuisfarmacie B.V. (defendant): Netherlands-based pharmacy company

Product Focus:

The dispute centers on semaglutide, the active ingredient in Novo Nordisk's blockbuster diabetes and weight-loss medications Ozempic and Wegovy. The case specifically involves a compounded nasal spray formulation of semaglutide.

Market Implications:

This legal victory strengthens Novo Nordisk's intellectual property protection for semaglutide as the company faces growing competition in the lucrative GLP-1 market. The injunction prevents Ceban from selling its compounded version in the Netherlands, protecting Novo's market exclusivity in the region.

The case highlights the broader challenge pharmaceutical companies face from compounding pharmacies, which have increasingly produced alternative formulations of popular weight-loss drugs amid supply shortages and high demand. By successfully blocking this competitor, Novo Nordisk demonstrates its willingness to aggressively defend its semaglutide patents across European markets.

This development is particularly significant as the global weight-loss drug market continues to expand rapidly, with semaglutide-based products generating billions in revenue for Novo Nordisk. The ruling sets a precedent for protecting branded pharmaceutical patents against compounded alternatives in Europe.

Timeline:

Announcement date: August 5, with the preliminary injunction already granted by the Dutch district court.